JP2017061467A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017061467A5 JP2017061467A5 JP2016202169A JP2016202169A JP2017061467A5 JP 2017061467 A5 JP2017061467 A5 JP 2017061467A5 JP 2016202169 A JP2016202169 A JP 2016202169A JP 2016202169 A JP2016202169 A JP 2016202169A JP 2017061467 A5 JP2017061467 A5 JP 2017061467A5
- Authority
- JP
- Japan
- Prior art keywords
- patients
- treatment
- formulation
- patient
- history
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161432245P | 2011-01-13 | 2011-01-13 | |
| US61/432,245 | 2011-01-13 | ||
| US201161434836P | 2011-01-21 | 2011-01-21 | |
| US61/434,836 | 2011-01-21 | ||
| US201161561957P | 2011-11-21 | 2011-11-21 | |
| US61/561,957 | 2011-11-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013549502A Division JP2014503555A (ja) | 2011-01-13 | 2012-01-11 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019104939A Division JP2019167366A (ja) | 2011-01-13 | 2019-06-05 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017061467A JP2017061467A (ja) | 2017-03-30 |
| JP2017061467A5 true JP2017061467A5 (https=) | 2017-05-18 |
Family
ID=45507924
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013549502A Withdrawn JP2014503555A (ja) | 2011-01-13 | 2012-01-11 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2016202169A Pending JP2017061467A (ja) | 2011-01-13 | 2016-10-14 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2019104939A Pending JP2019167366A (ja) | 2011-01-13 | 2019-06-05 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2021146749A Pending JP2021193115A (ja) | 2011-01-13 | 2021-09-09 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2023174006A Active JP7733706B2 (ja) | 2011-01-13 | 2023-10-06 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2025136675A Pending JP2025169389A (ja) | 2011-01-13 | 2025-08-20 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013549502A Withdrawn JP2014503555A (ja) | 2011-01-13 | 2012-01-11 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019104939A Pending JP2019167366A (ja) | 2011-01-13 | 2019-06-05 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2021146749A Pending JP2021193115A (ja) | 2011-01-13 | 2021-09-09 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2023174006A Active JP7733706B2 (ja) | 2011-01-13 | 2023-10-06 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
| JP2025136675A Pending JP2025169389A (ja) | 2011-01-13 | 2025-08-20 | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (14) | US9254338B2 (https=) |
| EP (4) | EP3763379A1 (https=) |
| JP (6) | JP2014503555A (https=) |
| KR (8) | KR20260004598A (https=) |
| CN (1) | CN103533950A (https=) |
| AU (5) | AU2012205599B2 (https=) |
| BR (1) | BR112013017752A8 (https=) |
| CA (1) | CA2824422A1 (https=) |
| HK (1) | HK1244693A1 (https=) |
| IL (3) | IL295359A (https=) |
| MX (3) | MX349901B (https=) |
| SG (4) | SG10201509193UA (https=) |
| WO (1) | WO2012097019A1 (https=) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007237096C1 (en) | 2006-04-07 | 2012-12-13 | EyePoint, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| KR20260004598A (ko) | 2011-01-13 | 2026-01-08 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| AU2012323856B2 (en) | 2011-10-13 | 2017-05-25 | EyePoint, Inc. | Methods for treating Vascular Leak Syndrome and cancer |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| WO2016005381A1 (en) * | 2014-07-10 | 2016-01-14 | Bayer Pharma Aktiengesellschaft | Pdgfrbeta-fc fusion proteins and uses thereof |
| TWI738632B (zh) * | 2014-11-07 | 2021-09-11 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| PT3230316T (pt) * | 2014-12-11 | 2022-02-24 | Bayer Healthcare Llc | Ratamento de degenerescência macular relacionada com a idade com uma pequena lesão de neovascularização coroideia ativa |
| US20180000816A1 (en) * | 2015-02-06 | 2018-01-04 | Unity Biotechnology, Inc. | Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions |
| CA2977738A1 (en) * | 2015-02-26 | 2016-09-01 | Feramda Ltd. | Compositions and combinations for the treatment of angiogenesis diseases and disorders |
| KR101808234B1 (ko) * | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| WO2017046140A1 (en) * | 2015-09-18 | 2017-03-23 | Bayer Pharma Aktiengesellschaft | Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia |
| CN108348777B (zh) | 2015-09-30 | 2020-04-28 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| US20180353464A1 (en) * | 2015-11-24 | 2018-12-13 | Indiana University Research And Technology Corporation | Composition for blocking angiogenesis |
| PT3384049T (pt) | 2015-12-03 | 2023-08-18 | Regeneron Pharma | Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf |
| KR102799807B1 (ko) | 2015-12-30 | 2025-04-24 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| RU2765728C2 (ru) * | 2016-05-25 | 2022-02-02 | Сантен Фармасьютикал Ко., Лтд. | Применение сиролимуса для лечения экссудативной возрастной макулярной дегенерации с персистирующим отеком |
| CN109937034B (zh) | 2016-11-21 | 2022-09-16 | 济世-伊沃泰克生物制品有限公司 | 阿柏西普制剂及其用途 |
| US20190388522A1 (en) * | 2017-01-25 | 2019-12-26 | Iconic Therapeutics, Inc. | Methods for treating disorders associated with angiogenesis and neovascularization |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| WO2019099786A1 (en) * | 2017-11-16 | 2019-05-23 | Ophthotech Corporation | A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (ipcv) |
| CA3081094A1 (en) | 2017-11-20 | 2019-05-23 | Alison J. GILLESPIE | Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof |
| EP4122486A1 (en) * | 2017-11-30 | 2023-01-25 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat diabetic retinopathy |
| FI3743091T3 (fi) | 2018-01-26 | 2025-01-03 | Univ California | Menetelmät ja koostumukset verisuoniperäisten sairauksien hoitoon käyttämällä anti-vegf vaikuttavia aineita |
| CN111699004A (zh) * | 2018-02-06 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| KR20200131839A (ko) * | 2018-03-16 | 2020-11-24 | 노파르티스 아게 | 안질환의 치료 방법 |
| US11103552B2 (en) | 2018-05-10 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | High concentration VEGF receptor fusion protein containing formulations |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| CN120058958A (zh) | 2018-09-24 | 2025-05-30 | 视点制药公司 | 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体 |
| EP3873519A1 (en) | 2018-10-29 | 2021-09-08 | F. Hoffmann-La Roche AG | Antibody formulation |
| CN113710228A (zh) | 2019-02-13 | 2021-11-26 | 诺瓦利克有限责任公司 | 用于治疗眼部新生血管形成的组合物和方法 |
| JP7561433B2 (ja) * | 2019-05-28 | 2024-10-04 | 学校法人順天堂 | 糖尿病網膜症の予防又は治療薬 |
| CN118718181A (zh) | 2019-06-05 | 2024-10-01 | 里珍纳龙药品有限公司 | 用于精确剂量递送的装置及方法 |
| AU2020345174A1 (en) * | 2019-09-12 | 2022-03-31 | Lupin Limited | Modified dosing of VEGF inhibitors for ophthalmic use |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021108255A1 (en) | 2019-11-25 | 2021-06-03 | The Regents Of The University Of California | Long-acting vegf inhibitors for intraocular neovascularization |
| AU2020397053A1 (en) | 2019-12-06 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | VEGF mini-traps and methods of use thereof |
| US11180540B2 (en) | 2019-12-06 | 2021-11-23 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
| KR102426802B1 (ko) * | 2019-12-23 | 2022-07-28 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질을 포함하는 신생혈관형성 관련 질환의 예방 및 치료를 위한 약학조성물 |
| JP2023525034A (ja) | 2020-05-08 | 2023-06-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法 |
| AU2021287906B2 (en) * | 2020-06-11 | 2025-09-11 | Alkahest Inc. | Methods of improving retina-associated disease outcome using CCR3-inhibitors |
| WO2022186335A1 (ja) * | 2021-03-03 | 2022-09-09 | 学校法人自治医科大学 | 副作用の予測方法およびそのための装置 |
| EP4649959A2 (en) * | 2021-04-14 | 2025-11-19 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| IL308505A (en) * | 2021-05-17 | 2024-01-01 | Regeneron Pharma | Continuous high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2024168252A2 (en) * | 2023-02-10 | 2024-08-15 | Yale University | Use of inhibitors of vegf-c signaling for inhibiting immune responses and increasing gene therapy efficacy |
| WO2024263995A1 (en) * | 2023-06-23 | 2024-12-26 | Regeneron Pharmaceuticals, Inc. | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders |
| TW202525324A (zh) * | 2023-08-17 | 2025-07-01 | 大陸商信達生物製藥（蘇州）有限公司 | 治療年齡相關性黃斑變性和糖尿病性黃斑水腫的方法 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CN100523187C (zh) | 1999-06-08 | 2009-08-05 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
| US7396664B2 (en) * | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| CA2454587C (en) | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| JP5290489B2 (ja) | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Ｉｇｇ抗体の安定な液体医薬製剤 |
| WO2003039404A2 (en) | 2001-11-09 | 2003-05-15 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
| JP2003309411A (ja) | 2002-04-17 | 2003-10-31 | Alps Electric Co Ltd | 複合アンテナ |
| WO2004072320A2 (en) | 2003-02-07 | 2004-08-26 | Pavco, Inc. | Use of n-allyl substituted amines and their salts as brightening agents in nickel plating baths |
| US7052691B2 (en) | 2003-03-28 | 2006-05-30 | Regeneron Pharmaceuticals, Inc. | Methods of treating diabetes by blocking VEGF-mediated activity |
| CN1798575A (zh) | 2003-04-04 | 2006-07-05 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
| US20040266688A1 (en) | 2003-05-14 | 2004-12-30 | Nayak Nihar R | Methods for modulating endometrium |
| AU2004242586C1 (en) | 2003-05-28 | 2011-02-24 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using VEGF antagonists |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| WO2005087808A2 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Growth factor binding constructs materials and methods |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| KR100897379B1 (ko) | 2004-06-08 | 2009-05-14 | 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 | 혈관신생-저해 키메릭 단백질 및 그 사용 |
| CN1304427C (zh) | 2004-06-08 | 2007-03-14 | 成都康弘生物科技有限公司 | 抑制血管新生的融合蛋白质及其用途 |
| EP1753442A2 (en) | 2004-06-10 | 2007-02-21 | Regeneron Pharmaceuticals, Inc. | Method of administering and using vegf inhibitors for the treatment of human cancer |
| MXPA06014689A (es) | 2004-06-18 | 2008-03-11 | Regeneron Pharma | Inhibidores del vegf para el tratamiento de efusion pleural maligna. |
| US7378095B2 (en) | 2004-07-30 | 2008-05-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating type I diabetes by blocking VEGF-mediated activity |
| PL1802334T3 (pl) | 2004-10-21 | 2013-01-31 | Genentech Inc | Sposób leczenia wewnątrzgałkowych chorób neowaskularnych |
| US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| CN102614134B (zh) | 2005-03-25 | 2016-09-07 | 瑞泽恩制药公司 | Vegf拮抗剂制剂 |
| EP1917024A2 (en) | 2005-08-12 | 2008-05-07 | Regeneron Pharmaceuticals, Inc. | Methods of treating diseases with a vegf antagonist |
| CN100567325C (zh) | 2006-03-31 | 2009-12-09 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用 |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| US7608261B2 (en) | 2006-06-16 | 2009-10-27 | Regeneron Pharmacuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
| CA2666709A1 (en) * | 2006-11-10 | 2008-05-29 | Genentech, Inc. | Method for treating age-related macular degeneration |
| FR2918279B1 (fr) | 2007-07-05 | 2010-10-22 | Aventis Pharma Sa | Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan |
| CN102233132B (zh) | 2010-04-28 | 2013-10-23 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用 |
| CN102380096B (zh) | 2010-08-31 | 2014-04-30 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
| KR20260004598A (ko) | 2011-01-13 | 2026-01-08 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| CN107115294B (zh) | 2012-01-19 | 2019-10-18 | 北京康弘生物医药有限公司 | 一种含有vegf拮抗剂的滴眼液 |
| JP6071099B1 (ja) | 2014-01-25 | 2017-02-01 | ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド | 血管の新生又は成長を抑制する融合タンパク質及びその用途 |
| TWI738632B (zh) | 2014-11-07 | 2021-09-11 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| EP4122486A1 (en) | 2017-11-30 | 2023-01-25 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat diabetic retinopathy |
-
2012
- 2012-01-11 KR KR1020257043583A patent/KR20260004598A/ko active Pending
- 2012-01-11 KR KR1020187004862A patent/KR20180023015A/ko not_active Ceased
- 2012-01-11 KR KR1020137018185A patent/KR20140043313A/ko not_active Ceased
- 2012-01-11 SG SG10201509193UA patent/SG10201509193UA/en unknown
- 2012-01-11 MX MX2013007847A patent/MX349901B/es active IP Right Grant
- 2012-01-11 EP EP20186662.1A patent/EP3763379A1/en not_active Withdrawn
- 2012-01-11 SG SG2013048798A patent/SG191334A1/en unknown
- 2012-01-11 CA CA2824422A patent/CA2824422A1/en active Pending
- 2012-01-11 KR KR1020197012536A patent/KR20190049934A/ko not_active Ceased
- 2012-01-11 KR KR1020227021482A patent/KR20220097542A/ko not_active Ceased
- 2012-01-11 WO PCT/US2012/020855 patent/WO2012097019A1/en not_active Ceased
- 2012-01-11 AU AU2012205599A patent/AU2012205599B2/en active Active
- 2012-01-11 KR KR1020247022007A patent/KR20240110092A/ko not_active Ceased
- 2012-01-11 SG SG10202111177VA patent/SG10202111177VA/en unknown
- 2012-01-11 KR KR1020217007359A patent/KR20210030510A/ko not_active Ceased
- 2012-01-11 EP EP17168808.8A patent/EP3222285A1/en not_active Withdrawn
- 2012-01-11 BR BR112013017752A patent/BR112013017752A8/pt not_active Application Discontinuation
- 2012-01-11 KR KR1020207018126A patent/KR20200077622A/ko not_active Ceased
- 2012-01-11 EP EP12700590.8A patent/EP2663325A1/en not_active Withdrawn
- 2012-01-11 EP EP24161447.8A patent/EP4360709A3/en active Pending
- 2012-01-11 JP JP2013549502A patent/JP2014503555A/ja not_active Withdrawn
- 2012-01-11 MX MX2017010249A patent/MX385629B/es unknown
- 2012-01-11 SG SG10201802789VA patent/SG10201802789VA/en unknown
- 2012-01-11 IL IL295359A patent/IL295359A/en unknown
- 2012-01-11 CN CN201280005207.7A patent/CN103533950A/zh active Pending
-
2013
- 2013-06-24 IL IL227160A patent/IL227160B/en active IP Right Grant
- 2013-07-04 MX MX2021006092A patent/MX2021006092A/es unknown
- 2013-07-12 US US13/940,370 patent/US9254338B2/en active Active
-
2015
- 2015-12-17 US US14/972,560 patent/US9669069B2/en active Active
-
2016
- 2016-10-14 JP JP2016202169A patent/JP2017061467A/ja active Pending
-
2017
- 2017-01-17 AU AU2017200290A patent/AU2017200290B2/en active Active
- 2017-03-28 US US15/471,506 patent/US10130681B2/en active Active
-
2018
- 2018-03-27 HK HK18104210.6A patent/HK1244693A1/en unknown
- 2018-06-20 IL IL260167A patent/IL260167A/en unknown
- 2018-08-06 US US16/055,847 patent/US10857205B2/en active Active
- 2018-10-12 US US16/159,282 patent/US10828345B2/en active Active
-
2019
- 2019-04-02 AU AU2019202260A patent/AU2019202260A1/en not_active Abandoned
- 2019-04-29 US US16/397,267 patent/US10888601B2/en active Active
- 2019-06-05 JP JP2019104939A patent/JP2019167366A/ja active Pending
-
2020
- 2020-10-16 US US17/072,417 patent/US11986511B2/en active Active
- 2020-12-04 US US17/112,063 patent/US11975045B2/en active Active
- 2020-12-04 US US17/112,404 patent/US11730794B2/en active Active
-
2021
- 2021-02-12 AU AU2021200935A patent/AU2021200935A1/en not_active Abandoned
- 2021-06-17 US US17/350,958 patent/US11707506B2/en active Active
- 2021-06-21 US US17/352,892 patent/US11253572B2/en active Active
- 2021-09-09 JP JP2021146749A patent/JP2021193115A/ja active Pending
-
2022
- 2022-05-10 US US17/740,744 patent/US11559564B2/en active Active
-
2023
- 2023-10-06 JP JP2023174006A patent/JP7733706B2/ja active Active
- 2023-10-27 US US18/496,472 patent/US12268730B2/en active Active
-
2024
- 2024-07-05 AU AU2024204677A patent/AU2024204677A1/en active Pending
-
2025
- 2025-01-17 US US19/027,212 patent/US20250152669A1/en active Pending
- 2025-08-20 JP JP2025136675A patent/JP2025169389A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017061467A5 (https=) | ||
| JP2024001190A (ja) | 血管新生眼疾患を処置するためのｖｅｇｆアンタゴニストの使用 | |
| CN110664757B (zh) | 纳米晶滴眼剂、其制备方法及其应用 | |
| KR101689847B1 (ko) | 디플루프레드네이트를 포함하는 황반부종 치료용 점안액 | |
| JP2022183183A (ja) | 小さい活動性脈絡膜新生血管病変を有する加齢黄斑変性症の治療 | |
| CA3025258C (en) | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema | |
| Donnenfeld et al. | Safety of IBI-10090 for inflammation associated with cataract surgery: phase 3 multicenter study | |
| WO2010004594A1 (en) | Ophthalmic compositions for treating pathologies of the posterior segment of the eye | |
| JP6675307B2 (ja) | 持続的薬物送達インプラントによる眼の状態の治療の方法 | |
| JP2016522250A (ja) | 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用 | |
| JP2016121163A (ja) | 眼内でのコルチコステロイド使用に伴う眼圧の発生を減少させる方法 | |
| WO2006088134A1 (ja) | ステロイド化合物の副作用軽減または回避方法 | |
| Veritti et al. | Triple therapy for anti-vascular endothelial growth factor nonresponders in neovascular age-related macular degeneration: impact of different photodynamic therapy parameters | |
| Park et al. | Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization in serpiginous choroiditis | |
| Kiernan et al. | Topical drug delivery for posterior segment disease | |
| Gull et al. | Intravitrealversus posterior subtenon triamcinolone acetonide in conjunction with intravitreal bevacizumab for refractory diabetic macular edema | |
| Andrijević-Derk et al. | Intravitreal bevacizumab for neovascular glaucoma | |
| Dubey et al. | Management of neovascular glaucoma | |
| Cervantes et al. | Injeção não intencional de implante de dexametasona no cristalino: relato de caso, acompanhamento e desfecho | |
| Augustin et al. | Suprachoroidal drug delivery–a new approach for the treatment of severe macular diseases | |
| Park et al. | Conjunctival nevus-like lesions originating from a sclerotomy site after 23-gauge transconjunctival sutureless vitrectomy | |
| HK40071471A (en) | Treatment of age related macular degeneration with a small active choroidal neovascularization lesion | |
| AU2023255001A1 (en) | Pharmaceutical composition for preventing or treating ocular disease comprising enavogliflozin | |
| US20050038103A1 (en) | Uses of dorzolamide | |
| CN118059213A (zh) | Pd-1在制备治疗眼部脉络膜新生血管药物中的应用 |